Samsung Medical Center

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Subsidiary

Established: 1994-01-01

Employees: 501

Market Cap: -

Website: http://www.samsunghospital.com

Clinical Trials

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

Phase 2

Completed

Conditions: Stomach Neoplasms

Interventions: Drug: Sunitinib
Drug: Imatinib
Drug: Gefitinib

First Posted Date: 2017-05-30

Last Posted Date: 2022-06-15

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 66

Registration Number: NCT03170180

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Effect of Intensive Language Therapy in Subacute Stroke Patients

Not Applicable

Completed

Conditions: Stroke
Rehabilitation
Language

Interventions: Procedure: language rehabilitation therapy

First Posted Date: 2017-05-30

Last Posted Date: 2024-03-07

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 150

Registration Number: NCT03168373

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Effect of Intensive Motor Rehabilitation in Subacute Stroke Patient

Not Applicable

Completed

Conditions: Rehabilitation
Stroke
Motor Function

Interventions: Procedure: Intensive motor rehabilitation

First Posted Date: 2017-05-30

Last Posted Date: 2024-03-07

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 196

Registration Number: NCT03168386

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Usual Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin on Coronary Atherosclerotic Plaque

Phase 4

Active, not recruiting

Conditions: Coronary Artery Disease

Interventions: Drug: Rosuvastatin 20 mg orally once a day
Drug: Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day

First Posted Date: 2017-05-30

Last Posted Date: 2024-04-22

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 280

Registration Number: NCT03169985

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Phase II Trial of Vistusertib（AZD2014） Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard Chemotherapy

Phase 2

Withdrawn

Conditions: Solid Tumor

First Posted Date: 2017-05-25

Last Posted Date: 2019-05-20

Lead Sponsor: Samsung Medical Center

Registration Number: NCT03166176

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy

Phase 2

Withdrawn

Conditions: Solid Tumor

Interventions: Drug: Vistusertib(AZD2014)

First Posted Date: 2017-05-25

Last Posted Date: 2019-05-20

Lead Sponsor: Samsung Medical Center

Registration Number: NCT03166904

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Serum BDNF Role as a Biomarker for Stroke Rehabilitation

Completed

Conditions: Biomarker
BDNF
Stroke
Rehabilitation

First Posted Date: 2017-05-24

Last Posted Date: 2020-03-18

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 150

Registration Number: NCT03164798

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib

Phase 2

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Pembrolizumab

First Posted Date: 2017-05-23

Last Posted Date: 2022-08-08

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 60

Registration Number: NCT03163992

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes

Phase 2

Completed

Conditions: Neuroendocrine Carcinoma, Grade 3

Interventions: Drug: Avelumab

First Posted Date: 2017-05-10

Last Posted Date: 2019-12-30

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 14

Registration Number: NCT03147404

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

The Efficacy and Safety of Udenafil in Patients With Erectile Dysfunction After Bilateral Nerve-sparing Radical Prostatectomy

Phase 4

Conditions: Prostate Cancer With Radical Prostatectomy

Interventions: Drug: ZYDENA TAB.75mg(Udenafil 75mg)
Drug: Placebo Oral Tablet

First Posted Date: 2017-05-05

Last Posted Date: 2017-05-05

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 99

Registration Number: NCT03142542

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy